

**ATRIAL REVERSE REMODELING IN HYPERTENSIVE  
SUBSTRATE**

**Shivshankar Thanigaimani. MS.**

**Centre for Heart Rhythm Disorders  
Royal Adelaide Hospital**

**&**

**School of Medicine  
The University of Adelaide**

**A thesis submitted to The University of Adelaide**

**in fulfillment of the requirements of the degree of**

**Doctor of Philosophy (Medicine & Surgery)**

**July 2014**

**ABSTRACT ..... viii**

**DECLARATION ..... xi**

**ACKNOWLEDGEMENT ..... xii**

**PUBLICATIONS AND COMMUNICATIONS TO  
LEARNED SOCIETIES ..... xiv**

**1            ATRIAL REMODELING: IMPLICATIONS FOR  
ATRIAL FIBRILLATION .....1**

**1.1        Introduction.....1**

**1.2        Mechanisms of AF .....3**

1.2.1 Early glimpses of AF: .....3

1.2.2 Initial AF theories: .....4

**1.3        Atrial remodeling due to AF: Mechanisms by which AF perpetuates  
itself        9**

1.3.1 Electrical remodeling ..... 10

1.3.2 Structural remodeling ..... 12

1.3.3 Ion channel remodeling ..... 14

**1.4        Atrial remodeling in substrates predisposed to AF .....16**

1.4.1 Hypertension ..... 16

1.4.2 Congestive heart failure .....20

1.4.3 Mitral stenosis.....21

1.4.4 Aging .....22

1.4.5	Myocardial ischemia.....	22
1.4.6	Obesity.....	23
1.4.7	Obstructive sleep apnea.....	24
1.4.8	Atrial septal defect.....	25
1.4.9	Atrial stretch.....	26
1.4.10	Aortic stiffness.....	28
1.4.11	Smoking.....	29
1.4.12	Alcohol.....	29
<b>1.5</b>	<b>Reverse remodeling of atrial substrate.....</b>	<b>30</b>
<b>1.6</b>	<b>Prevention of atrial remodeling.....</b>	<b>32</b>
<b>1.7</b>	<b>Summary.....</b>	<b>35</b>
<b>2</b>	<b>Characterisation of reverse structural remodeling of hypertensive atria with anti-hypertensive treatment: Implications for Atrial fibrillation.....</b>	<b>36</b>
<b>2.1</b>	<b>Introduction.....</b>	<b>36</b>
<b>2.2</b>	<b>Methods.....</b>	<b>37</b>
2.2.1	Study approval and guidelines.....	37
2.2.2	Animal housing & preparation.....	38
2.2.3	‘One-kidney, one-clip’ Renovascular Hypertension model.....	38
2.2.4	Cardiac MR Imaging.....	40
2.2.5	Study Timeline.....	41
2.2.6	Anatomical/ Structural Analysis.....	41

2.2.7	Statistical Analysis.....	43
<b>2.3</b>	<b>Results .....</b>	<b>44</b>
2.3.1	Blood Pressure .....	44
2.3.2	Cardiac Functional and Morphological Assessment .....	44
2.3.3	Histological Examination .....	45
2.3.4	Immunostaining .....	47
<b>2.4</b>	<b>Discussion .....</b>	<b>49</b>
2.4.1	Structural Remodeling in Hypertensive Atria .....	49
2.4.2	Reverse structural remodeling in humans and other animal models .....	51
2.4.3	Reverse remodeling and class of anti-hypertensive agents .....	52
2.4.4	Clinical implications .....	53
2.4.5	Limitations .....	53
<b>2.5</b>	<b>Conclusions.....</b>	<b>54</b>
<b>2.6</b>	<b>Figures.....</b>	<b>55</b>
<b>2.7</b>	<b>Tables .....</b>	<b>63</b>

### **3 CHARACTERISATION OF ELECTRICAL ‘REVERSE’ REMODELING OF HYPERTENSIVE ATRIA WITH PHARMACOLOGICAL INTERVENTION .....65**

<b>3.1</b>	<b>Introduction.....</b>	<b>65</b>
<b>3.2</b>	<b>Methods.....</b>	<b>66</b>
3.2.1	Study approval and guidelines .....	66

3.2.2	Animal Housing & Preparation .....	67
3.2.3	Study timeline: .....	67
3.2.4	‘One Kidney One Clip’ renovascular hypertension Model .....	68
3.2.5	Electrophysiological study .....	70
3.2.6	Statistics .....	73
<b>3.3</b>	<b>Results .....</b>	<b>73</b>
3.3.1	Blood pressure measurements .....	74
3.3.2	Atrial electrophysiological reverse remodeling .....	74
<b>3.4</b>	<b>Discussion .....</b>	<b>78</b>
3.4.1	Reverse remodeling of abnormal atrial substrate .....	79
3.4.2	Electrogram characteristics during reverse remodeling.....	81
3.4.3	Clinical implications .....	82
3.4.4	Limitations .....	83
<b>3.5</b>	<b>Conclusions.....</b>	<b>83</b>
<b>3.6</b>	<b>Figures.....</b>	<b>84</b>
<b>4</b>	<b>Prevention of structural remodeling of hypertensive atria with pharmacological intervention: Effect of Novel anti-fibrotic drug .....</b>	<b>95</b>
<b>4.1</b>	<b>Introduction: .....</b>	<b>95</b>
<b>4.2</b>	<b>Methods.....</b>	<b>96</b>
4.2.1	Study approval and guidelines .....	96
4.2.2	Animal housing & preparation .....	96

4.2.3	‘One-kidney, one-clip’ Renovascular Hypertension model .....	97
4.2.4	Cardiac MR Imaging .....	99
4.2.5	Study timeline:.....	100
4.2.6	Anatomical/ Structural Analysis .....	100
4.2.7	Statistical Analysis.....	102
<b>4.3</b>	<b>Results:.....</b>	<b>102</b>
4.3.1	Blood pressure measurements .....	103
4.3.2	Cardiac MRI assessment.....	103
4.3.3	Histological examination .....	104
4.3.4	Immunostaining .....	105
<b>4.4</b>	<b>Discussion .....</b>	<b>106</b>
4.4.1	Structural remodeling in various models .....	107
4.4.2	Prevention of structural remodeling in various models .....	108
<b>4.5</b>	<b>Limitations.....</b>	<b>110</b>
<b>4.6</b>	<b>Conclusions.....</b>	<b>110</b>
<b>4.7</b>	<b>Figures.....</b>	<b>111</b>
<b>4.8</b>	<b>Tables .....</b>	<b>118</b>
<b>5</b>	<b>Prevention of electrical remodeling of hypertensive atria with tranilast, a novel anti-fibrotic drug .....</b>	<b>120</b>
<b>5.1</b>	<b>Introduction: .....</b>	<b>120</b>
<b>5.2</b>	<b>Methods.....</b>	<b>121</b>

5.2.1	Study approval and guidelines .....	121
5.2.2	Animal housing & Preparation .....	121
5.2.3	Study timeline:.....	122
5.2.4	‘One-kidney, one-clip’ renovascular hypertension model.....	122
5.2.5	Electrophysiological study.....	124
5.2.6	Statistics .....	127
<b>5.3</b>	<b>Results .....</b>	<b>128</b>
5.3.1	Blood pressure measurements .....	128
5.3.2	Atrial electrophysiological reverse remodeling .....	128
<b>5.4</b>	<b>Discussion .....</b>	<b>131</b>
5.4.1	Prevention of atrial electrical remodeling.....	132
5.4.2	Role of anti-fibrotic drugs in preventing atrial electrical remodeling .....	133
5.4.3	Clinical implications .....	134
5.4.4	Limitations .....	134
<b>5.5</b>	<b>Conclusions.....</b>	<b>134</b>
<b>5.6</b>	<b>FIGURES.....</b>	<b>136</b>

## **6 Spatio-temporal characteristics of atrial fibrillation electrograms in self-terminating versus sustained AF episodes 145**

<b>6.1</b>	<b>Introduction: .....</b>	<b>145</b>
<b>6.2</b>	<b>Methods: .....</b>	<b>147</b>
6.2.1	Direct contact mapping.....	147

6.2.2	Atrial fibrillation episodes .....	148
6.2.3	Spatio-temporal stability index .....	148
6.2.4	AF electrogram analysis .....	150
6.2.5	Statistics: .....	151
<b>6.3</b>	<b>Results:.....</b>	<b>152</b>
6.3.1	Spatio-temporal stability in the initiation phase of self-terminating versus sustained AF episodes.....	153
6.3.2	Spatio-temporal stability with sustained AF.....	153
6.3.3	Significant changes prior to termination in self-terminating AF episodes	154
<b>6.4</b>	<b>Discussion .....</b>	<b>154</b>
6.4.1	Do CFAE and DF sites represent substrates for AF? .....	155
6.4.2	Poor spatio-temporal stability of AF electrograms.....	157
6.4.3	Clinical Implications .....	158
<b>6.5</b>	<b>Limitations.....</b>	<b>158</b>
<b>6.6</b>	<b>Conclusions.....</b>	<b>159</b>
<b>6.7</b>	<b>Figures.....</b>	<b>160</b>
<b>7</b>	<b>FINAL DISCUSSIONS &amp; FUTURE DIRECTIONS.....</b>	<b>167</b>
<b>8</b>	<b>REFERENCES .....</b>	<b>169</b>



## ABSTRACT

Hypertension is a major independent risk factor for atrial fibrillation (AF). Despite various clinical and experimental studies on atrial remodeling in hypertensive substrates, pre-clinical experimental studies involving the prevention and treatment of electrical and structural changes secondary to hypertension remain limited. Many antihypertensive drugs have been shown to reduce AF recurrence in patients with hypertension. Additionally, recent work suggests that anti-fibrotic drug, Tranilast, has beneficial effects in preventing AF. This thesis focuses on the electrophysiological and structural effects with anti-fibrotic and anti-hypertensive therapies in hypertensive large animal model.

Chapter 1 details the theoretical mechanisms involved in the initiation and maintenance of AF and various conditions that contributes to abnormal atrial substrate formation. Importantly, studies involving reverse remodeling of various substrates and possible prevention of pathological atrial remodeling are also discussed.

Chapter 2 details the histological, anatomical and molecular changes in the hypertensive atria. We demonstrated that hypertension resulted in structural remodeling through increased myocyte hypertrophy, endomysial and interstitial fibrosis and inflammation along with increased septal thickness, which was contributed by increased CTGF and TGF- $\beta_1$  and reduced connexin43 expressions. Further, we showed that anti-hypertensive treatments could reverse all these pathological changes. This highlights the important

role of aggressive blood pressure lowering therapy in patients with AF and hypertension.

Chapter 3 illustrates the reverse electrical remodeling of hypertensive substrate using anti-hypertensive therapies. Significant improvement in conduction abnormalities and reduction in susceptibility to AF were seen with anti-hypertensive treatments. This further affirms the importance of blood pressure control in patients with hypertension and AF.

Chapter 4 details the histological, anatomical and molecular changes leading to the prevention of remodeling process in hypertensive atria. Tranilast (anti-fibrotic) treatment resulted in prevention of atrial structural remodeling by preventing myocyte hypertrophy, endomysial and interstitial fibrosis, inflammation, septal thickness and altered CTGF, TGF- $\beta_1$  and connexin43 expression levels.

Chapter 5 illustrates the prevention of atrial electrical remodeling in hypertensive atria with tranilast treatment during the development of high blood pressure. The results showed a reduced susceptibility to AF by preventing conduction slowing and heterogeneity seen with hypertension. Importantly, the beneficial effects seen in chapter 4 & 5 with tranilast treatment were independent of blood pressure levels.

Chapter 6 examines the fibrillatory electrograms in hypertensive atria. Complex fractionated atrial electrograms (CFAE) and dominant frequency (DF) are thought to

represent substrate sites in AF. A novel index of spatio-temporal stability (STS) was used in this study. We found that STS of CFAE was able to better predict AF termination than absolute mean fractionation values.

## DECLARATION

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

## **ACKNOWLEDGEMENT**

I would like to thank Professor Prashanthan Sanders, my primary supervisor for his guidance and support during my doctoral candidature. I also would like to thank Dr. Dennis Lau, my co-supervisor for his immense support. I am also thankful to my co-supervisors Dr. Anthony G. Brooks and Dr. Pawel Kuklik for their support and supervision over the duration of my candidature in particular with understanding statistical methods and analysis. Both my supervisor and co-supervisors helped me develop my research and scientific writing skills. I learned extensively from their meticulous supervision. I am grateful to all my mentors for helping me develop competitive research skills. I am also grateful for the scholarship support from the University of Adelaide and Peter Hetzel Electrophysiological Scholarship during my doctoral degree.

I appreciate the research environment provided by Centre for Heart Rhythm disorders members. I would like to also acknowledge Dr. Rajiv Mahajan, Dr. Anand Ganesan and Dr. Kurt Roberts Thomson for their constructive inputs to this work. I am also thankful to Dr. Srinivasan Govindarajan for his assistance with MRI scans and analysis.

I am very grateful to Dr. Mohan Rao and Dr. Timothy Kuchel who taught me the surgical procedures involved with this study. I am also thankful to the members of LARIF: Dr. Susan Porter, Ms. Loren Mathews, Ms. Carol Hewitt, Ms. Samantha

Herzog and Mr. Maurice Malycha. This study would have been impossible without their significant contribution.

Finally, I would like to thank my father: Thanigaimani Balaraman; mother: Lourdes Juliet Thanigaimani and my brother: Prabhu Shankar for their immense support during all these years. I am very grateful to my friends Raghuvveeran Anbalagan, Vimal Ganesh and Walter Clint Fernando for their encouragement and support during the exciting times of my candidature. Last, but not least, I was blessed with the understanding and immense support from my fiancée, Dr. Saranya Hariharan during my doctoral studies.

# **PUBLICATIONS AND COMMUNICATIONS TO LEARNED SOCIETIES**

## **Chapter 2 & 3:**

**Conference proceedings: Shivshankar Thanigaimani, Dennis H. Lau, Anthony G. Brooks, Pawel Kuklik, Rajiv Mahajan, Timothy Kuchel and Prashanthan Sanders. Reverse remodeling of the atrial substrate in hypertensive ovine model: Implications of conventional anti-hypertensive drugs. Cardiac society of Australia and New Zealand, Gold coast, Australia. Heart Lung and Circulation. 2013. Vol 22; Page – S99..**

**Conference proceedings: Shivshankar Thanigaimani, Dennis H. Lau, Anthony G. Brooks, Pawel Kuklik, Rajiv Mahajan, Timothy Kuchel and Prashanthan Sanders. Reverse remodeling of the atrial substrate in a hypertensive ovine model: A chronic pharmacological intervention study. 34<sup>th</sup> Annual scientific sessions of the Heart rhythm society, Denver, CO, USA. Heart Rhythm. 2013. (May supplement) Page – 236.**

## **Chapter 4 & 5:**

**Conference proceedings: Shivshankar Thanigaimani, Anthony G. Brooks, Rajiv Mahajan, Pawel Kuklik, Darragh Twomey, Rajeev Pathak, Darren Kelly, Prashanthan Sanders, Dennis H. Lau. Tranilast has similar efficacy as anti-hypertensive drugs in prevention of atrial remodeling during hypertension. 35<sup>th</sup> Annual scientific sessions of**

the Heart rhythm society, California, San Francisco, USA. Heart Rhythm. 2014 (May supplement)..

## **Chapter 6:**

**Conference proceedings: Shivshankar Thanigaimani, Dennis H. Lau, Anthony G. Brooks, Pawel Kuklik, Anand Ganesan and Prashanthan Sanders. Spatio temporal differences in bipolar electrogram characteristics: Shannon entropy and frequency domain as predictive parameters of AF termination. Cardiac society of Australia and New Zealand. Gold coast, Australia. Hear Lung and Circulation. 2013. Vol 22; Page – S100.**

**Conference proceedings: Shivshankar Thanigaimani, Dennis H. Lau, Pawel Kuklik, Anthony G. Brooks, Anand Ganesan and Prashanthan Sanders. Differences in bipolar electrogram characteristics during AF initiation and pre-termination: Comparing Shannon entropy with time and frequency domain measures. 34<sup>th</sup> Annual scientific sessions of the Heart rhythm society, Denver, CO, USA. Heart Rhythm. 2013. (May supplement) Page – 254.**

**Conference proceedings: Shivshankar Thanigaimani, Pawel Kuklik, Anthony Brooks, Anand Ganesan, Rajiv Mahajan, Julia Kim, Prashanthan Sanders, and Dennis H. Lau. Dominant frequency rather than electrogram fractionation plays a role in atrial**



fibrillation initiation in hypertensive atria. Faculty of Health sciences Postgraduate research conference (2012). University of Adelaide.

**Conference proceedings: Shivshankar Thanigaimani, Pawel Kuklik, Anthony Brooks, Anand Ganesan, Rajiv Mahajan, Julia Kim, Prashanthan Sanders, and Dennis H. Lau, .** Time and frequency domain analysis of atrial electrograms during the initiation and pre-termination of atrial fibrillation in hypertensive sheep with remodeled atria. 2012. The 5<sup>th</sup> Asia pacific heart rhythm society scientific sessions in conjunction with 8<sup>th</sup> Asia pacific atrial fibrillation symposium. Journal of Arrhythmia. 2012. Vol 28; Supplement.10; Page 704.

**Conference proceedings: Shivshankar Thanigaimani, Dennis H. Lau, Pawel Kuklik, Anand Ganesan, Julia Kim, Rajiv Mahajan, Anthony Brooks, and Prashanthan Sanders.** Spatio-temporal profile of dominant frequency and complex fractionated atrial electrograms during atrial fibrillation in sheep with induced hypertension. 33<sup>rd</sup> Annual scientific sessions of the Heart rhythm society, Massachusetts, USA. Heart Rhythm 2012. Vol 9, No 5 (May supplement) Page – S333.